TRML Stock Overview
Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tourmaline Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.00 |
| 52 Week High | US$48.31 |
| 52 Week Low | US$12.12 |
| Beta | 0 |
| 11 Month Change | -15.21% |
| 3 Month Change | 68.54% |
| 1 Year Change | 34.15% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 120.18% |
Recent News & Updates
Shareholder Returns
| TRML | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.6% | -6.5% | -1.0% |
| 1Y | 34.2% | 14.6% | 30.3% |
Return vs Industry: TRML exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: TRML exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| TRML volatility | |
|---|---|
| TRML Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TRML has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TRML's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 74 | Sandeep Kulkarni | www.tourmalinebio.com |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
Tourmaline Bio, Inc. Fundamentals Summary
| TRML fundamental statistics | |
|---|---|
| Market cap | US$602.60m |
| Earnings (TTM) | -US$63.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs TRML overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRML income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$63.88m |
| Earnings | -US$63.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRML perform over the long term?
See historical performance and comparison